Biocryst Pharmaceuticals Inc.’s near-term dilution should "pave the way for entrenchment" in the hereditary angioedema (HAE) space, thanks to the buyout of Astria...
Breaking up isn’t so hard to do, it seems. Just two years after spinning off its consumer products as Kenvue Inc., Johnson & Johnson aims to part ways with its orthopedics...
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, showed a new epigenetic...
In a deal that could top 2ドル billion, China-based Innocare Pharma Ltd. licensed the exclusive worldwide development and commercialization rights to the BTK inhibitor...
Play buttonBioxcel Therapeutics Inc.’s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients' homes for easier treatment.